November 12, 1997
Federal-Mogul Corp., the Southfield, Mich.-based maker of automobile parts, plans to close 13 service centers by the end of the year, eliminating 25 to 30 jobs, in a move to cut costs and improve its distribution system. . . . ING Group of Amsterdam offered to buy Banque Bruxelles Lambert for $4.68 billion in cash, stock and warrants in a bid to expand its business in Belgium. ING already owns 20% of BBL. . . . Electronics company Kemet Corp. of Greenville, S.C.
December 4, 2001 |
Cephalon Inc., which makes neurological drugs, agreed to buy French drug maker Group Lafon for $450 million in cash. By gaining full control of Lafon's Provigil drug for narcolepsy, Cephalon expects to add about $80 million in sales and 3 cents a share to earnings in 2002. The West Chester, Pa.-based drug maker increased its 2002 earnings forecast to $1.03 a share. Sales will be $400 million to $410 million, Cephalon said.
June 20, 2008 |
Government regulators said they were preparing to allow highly addictive medications to be prescribed online, a goal long sought by health insurers and large employers. Doctors are required by law to write out by hand prescriptions for controlled substances, which include attention deficit disorder drugs such as Shire Pharmaceuticals' Adderall and painkillers like Cephalon Inc.'s Fentora, which is for cancer patients. The concern is that patients are more likely to abuse these treatments, and their prescriptions should be monitored more closely.
March 6, 2007 |
Rep. Henry A. Waxman (D-Los Angeles) opened an investigation of research and marketing related to medical devices and drugs made by Boston Scientific Corp., Johnson & Johnson, Eli Lilly & Co., AstraZeneca and Cephalon Inc. The companies received letters from Waxman, chairman of the House Oversight and Government Reform Committee, asking for documents including correspondence with the Food and Drug Administration.
April 29, 1998 |
Cephalon Inc. and Chiron Corp. are talking with the Food and Drug Administration as it nears a decision on whether they can market their Lou Gehrig's disease treatment, Myotrophin, in the U.S. "We are still in the throes of protracted discussions with the FDA on Myotrophin," said Edward Penhoet, chief executive and president of Emeryville-based Chiron. "We expect it will be decided one way or the other by May 12."
July 11, 1995 |
Amgen Inc., the Thousand Oaks biotechnology firm, says encouraging test results have been obtained for a drug it is co-developing with a New York firm to treat amyotrophic lateral sclerosis, or Lou Gehrig's disease. Results have been encouraging enough to begin a third-phase trial, said Amgen and its partner in the project, Regeneron Pharmaceuticals Inc. of Tarrytown, N.Y.